DGAP-News

Oxford Immunotec receives 2014 Queen's Award for Enterprise - Seite 2

including the United States, where it has received pre-market approval from the
Food and Drug Administration, Europe, where it has obtained a CE mark, as well
as Japan and China. The Company is headquartered near Oxford, UK and in
Marlborough, MA and the Company's shares are traded on The NASDAQ Global Market
(Nasdaq:OXFD).

Oxford Immunotec was founded in 2002 to commercialise science originating from
the University of Oxford. The Company now employs over 150 people in the UK,
Continental Europe, US and Japan.

Additional information can be found at www.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.

About The Queen's Award Scheme

The Queen's Awards Scheme, originally known as The Queen's Award to Industry,
was instituted by Royal Warrant in 1965 and the first awards were made in 1966.
HM The Queen makes the Awards on the advice of the Prime Minister who is
assisted by an Advisory Committee that includes representatives of Government,
industry and commerce, and the trade unions. They are announced annually on 21
April, The Queen's birthday, and are only given for the highest levels of
excellence demonstrated in each category. Winners of The Queen's Awards can
expect an invitation to attend a special reception at Buckingham Palace.

For further information please visit www.queensawards.org.uk.

Forward-Looking Statements

This release contains forward-looking statements, including statements
regarding future success of the company. These forward-looking statements are
subject to risks and uncertainties that could cause actual results to differ
materially. Forward-looking statements are based on current expectations and
assumptions and currently available data and are neither predictions nor
guarantees of future events or performance. You should not place undue reliance
on forward-looking statements, which speak only as of the date of this
presentation. We do not undertake to update or revise any forward-looking
statements after they are made, whether as a result of new information, future
events, or otherwise, except as required by applicable law.

CONTACTS:

For Media Inquiries:
Caroline Crawley
Oxford Immunotec
Tel: [phone]
[e-mail]

For Investor Inquiries:
Rick Altieri
Chief Financial Officer,
Oxford Immunotec
Tel: [phone]
[e-mail]

Mark Klausner
Westwicke Partners
Tel: [phone]
[e-mail]
News Source: NASDAQ OMX


End of Corporate News

---------------------------------------------------------------------

21.04.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language: English
Company: Oxford Immunotec


Großbritannien
ISIN: GB00BGFBB958


End of News DGAP News-Service
---------------------------------------------------------------------
263900 21.04.2014